자동화 및 밀폐형 세포치료 시장 : 전략적 분석과 예측(2026-2031년)

The Automated and Closed Cell Therapy Market is expected to grow at a 15.68% CAGR, increasing to USD 4.236 billion in 2031 from USD 1.768 billion in 2025.

The automated and closed cell therapy market is undergoing significant transformation driven by the commercialization of advanced cell therapies, pressure to reduce manufacturing variability, and regulatory emphasis on process control and data integrity. The market's evolution is characterized by the growing recognition that automated closed systems provide essential capabilities for manufacturing reproducibility, contamination control, and operational efficiency, enabling the transition from labor-intensive manual workflows to scalable commercial production. The convergence of regulatory requirements, manufacturing economics, and process standardization is reshaping how pharmaceutical companies, biotechnology developers, and contract manufacturing organizations approach cell therapy production. Early cell therapy manufacturing often relied on open systems, multiple manual handling steps, and fragmented equipment workflows that become difficult to manage when manufacturers seek larger batch volumes, multi-site production, or broader geographic distribution. The market is witnessing significant investment in integrated manufacturing platforms, digital process documentation, and closed-system technologies, positioning automation as a strategic necessity for cell therapy commercialization rather than a secondary operational consideration.

Market Drivers

• The commercialization of advanced cell therapies represents the primary driver for the automated and closed cell therapy market. Regulatory approvals for cellular therapies have increased the importance of manufacturing scalability. While research-stage production can tolerate higher levels of manual intervention, commercial supply chains require repeatable processes, reliable batch performance, and greater operational efficiency. Manufacturers expanding beyond clinical production are investing in automated closed systems to support larger patient populations while maintaining product quality standards. With more than 40 FDA-approved cell and gene therapy products globally by 2025, commercial manufacturing requirements continue expanding.
• Pressure to reduce manufacturing variability is accelerating the adoption of closed production systems. Process inconsistency remains one of the most closely monitored risks in cell therapy production. Variability can arise from operator handling, environmental exposure, equipment differences, and process deviations. Automated closed systems reduce manual touchpoints and support standardized workflows, making them attractive to developers seeking predictable manufacturing outcomes across multiple production sites. The reduction of dozens of operator-dependent steps in traditional workflows is a key driver for automation adoption.
• Regulatory focus on process control and data integrity is influencing manufacturing investment decisions. Regulatory agencies increasingly evaluate manufacturing controls alongside clinical performance. Process traceability, electronic records, environmental monitoring, and batch reproducibility have become important components of regulatory review. Automated platforms provide integrated process documentation and digital tracking capabilities that help manufacturers satisfy evolving compliance requirements. Regulatory inspection focus on process consistency and traceability supports the business case for closed systems.
• The expansion of allogeneic cell therapy development programs is creating demand for scalable production systems. Unlike autologous therapies, allogeneic products aim to serve larger patient populations from centralized manufacturing operations. This approach requires scalable production systems capable of processing larger cell volumes while maintaining product consistency. Equipment suppliers are responding through investments in automated bioreactor technologies, integrated cell-processing platforms, and advanced monitoring systems. Allogeneic approaches require larger-scale manufacturing capabilities and greater process standardization.
• Manufacturing labor constraints are increasing interest in automation as a workforce efficiency strategy. Cell therapy production requires specialized personnel trained in aseptic processing, quality systems, and advanced biologics manufacturing. Several industry participants have identified workforce availability as a challenge for facility expansion. Automation reduces dependence on highly specialized operators and allows facilities to increase throughput without proportional increases in staffing levels.

Market Restraints

• High capital requirements for the manufacturing transition create financial barriers for smaller developers. Moving from manual or semi-manual workflows to fully automated closed manufacturing often requires substantial investment in equipment, facility redesign, software infrastructure, process validation, and workforce training. Smaller biotechnology companies may struggle to justify these expenditures before achieving commercial revenue or securing long-term manufacturing demand. The transition from research to commercial manufacturing requires significant capital investment.
• Limited process standardization across therapies constrains platform scalability and increases implementation complexity. Cell therapies differ considerably in cell source, expansion methods, processing requirements, and quality specifications. A manufacturing platform optimized for one therapy may require significant modification for another. This limits the degree of standardization achievable across the industry and increases implementation complexity for equipment suppliers. The diversity of cell therapy approaches presents challenges for platform standardization.
• Lengthy validation and qualification cycles extend implementation timelines and delay anticipated productivity benefits. Cell therapy manufacturers operate within highly regulated environments where equipment changes can trigger extensive qualification activities. Introducing automated platforms often requires process comparability studies, documentation updates, and regulatory engagement. These requirements can extend implementation timelines and delay anticipated productivity benefits.
• Supply-chain dependence for specialized consumables creates operational risks and reduces manufacturing flexibility. Closed manufacturing systems frequently depend on proprietary tubing sets, single-use assemblies, reagents, sensors, and disposable components. Disruptions affecting these specialized inputs can reduce manufacturing flexibility and create operational risks. Several bioprocessing suppliers have expanded production capacity and supplier diversification efforts in response to these concerns.
• Economic uncertainty around large-scale deployment affects investment decisions. Although automation can improve efficiency, economic benefits vary according to therapy type, patient volume, reimbursement environment, and manufacturing model. Developers operating small patient populations may find that automation delivers lower financial returns than expected, particularly when capital costs remain high relative to production volumes.

Technology and Segment Insights

• The technology landscape is characterized by the growing importance of integrated manufacturing platforms, closed-system processing, and digital process documentation. The Commercial Scale segment represents the most strategically important area because it directly influences the ability of approved therapies to reach larger patient populations. Clinical-stage manufacturing often prioritizes flexibility and process experimentation, whereas commercial operations require validated processes, controlled costs, consistent quality outcomes, and dependable supply chains. These requirements align closely with the capabilities offered by automated closed manufacturing platforms.
• Purchasing criteria within the commercial scale segment differ substantially from those observed in research environments. Commercial operators prioritize batch reproducibility, facility throughput, regulatory readiness, digital integration, and long-term operating economics. Equipment performance remains important, but buyers increasingly evaluate complete manufacturing ecosystems that combine hardware, consumables, software, process analytics, and service support. Competition within the commercial-scale segment is increasingly focused on platform integration, with suppliers developing end-to-end manufacturing solutions that reduce handoffs between processing steps and simplify technology transfer activities.
• The Stem-Cell Therapy segment represents a major therapy type due to the diversity of clinical applications and commercial programs. Non-Stem-Cell Therapy, including CAR-T and other engineered cell therapies, drives demand for advanced automation due to complex patient-specific workflows. The Pharmaceuticals and Bio-Tech Companies end-user segment accounts for the largest share of investment, with these organizations leading commercial-scale manufacturing deployment.
• The integration of digital manufacturing records and process analytics is becoming increasingly important as suppliers develop platforms that support data integrity, regulatory compliance, and operational efficiency. Closed manufacturing systems align with regulatory objectives because they reduce environmental exposure, improve process documentation, and support standardized operating procedures. Equipment providers increasingly compete on process flexibility, scalability, data integration, and regulatory compliance support rather than hardware performance alone.

Competitive and Strategic Outlook

• The competitive landscape is characterized by a technology-driven and regulation-sensitive environment in which competitive positioning depends on equipment capabilities, process integration, regulatory support, service infrastructure, software functionality, and manufacturing expertise. Miltenyi Biotec, Lonza, Sartorius AG, and Thermo Fisher Scientific, Inc. have expanded investments in integrated manufacturing solutions that connect cell processing, analytics, software, and consumables. Their strategies reflect growing customer demand for standardized manufacturing environments capable of supporting both development and commercial operations.
• Danaher Corporation, through its life sciences businesses, continues to strengthen process automation and bioprocessing capabilities. Merck KGaA and Terumo Corporation maintain strong positions in cell processing technologies, while Fresenius Kabi leverages broader biopharmaceutical manufacturing expertise. Emerging participants such as Cellares Inc. are pursuing highly automated manufacturing models designed to reduce labor intensity and increase throughput. BioSpherix, LLC and ThermoGenesis focus on specialized manufacturing and controlled-environment solutions.
• Competitive differentiation depends on the ability to deliver integrated platforms that reduce process development risk, simplify technology transfer, and support regulatory compliance. Barriers to entry remain relatively high because suppliers must combine engineering expertise, regulatory understanding, bioprocessing knowledge, software integration capabilities, and long-term customer support. Qualification requirements and switching costs further strengthen relationships between established suppliers and commercial manufacturers.
• Recent key developments highlight the industry's focus on automated platforms, integrated quality control, and scalable manufacturing. Thermo Fisher Scientific launched the Gibco CTS Compleo Fill and Finish System, an automated, functionally closed platform streamlining cell therapy formulation and filling. Green Elephant Biotech launched Archimedes One, a dynamic adherent bioreactor reducing manual processing complexity. Sartorius introduced the Eveo Cell Therapy Platform, an integrated automated manufacturing and quality-control solution enabling multi-parallel autologous production. US WorldMeds completed the acquisition of Adaptimmune's cell therapy assets, strengthening its advanced therapy portfolio.
• North America remains the primary center for clinical commercialization and manufacturing deployment, with the United States leading in FDA approvals, biotechnology investment, and CDMO networks. European demand is supported by ATMP regulations and growing commercial manufacturing investments. Asia Pacific is expanding investments in advanced biopharmaceutical manufacturing, with China, Japan, South Korea, and India increasing biomanufacturing capacity.

Short Conclusion

• The automated and closed cell therapy market is positioned for robust growth driven by the convergence of cell therapy commercialization, regulatory expectations, and manufacturing cost pressures. The transition from manual, open workflows to automated, closed manufacturing represents a fundamental shift in cell therapy production, supported by regulatory guidance and economic necessity. While challenges related to capital costs, process standardization, and validation complexity persist, strategic investments in integrated platforms, digital process documentation, and scalable manufacturing solutions are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with automated closed systems evolving as essential infrastructure for cell therapy commercialization, supporting patient access, manufacturing consistency, and regulatory compliance across the advanced therapeutics industry.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. AUTOMATED AND CLOSED SELL THERAPY MARKET BY THERAPY TYPE

• 5.1. Introduction
• 5.2. Stem-Cell Therapy
• 5.3. Non-Stem-Cell Therapy

6. AUTOMATED AND CLOSED SELL THERAPY MARKET BY SCALE

• 6.1. Introduction
• 6.2. Pre-Commercial / R&D Scale
• 6.3. Commercial Scale

7. AUTOMATED AND CLOSED SELL THERAPY MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceuticals and Bio-Tech Companies
• 7.3. Research and Academic Institute
• 7.4. Others

8. AUTOMATED AND CLOSED SELL THERAPY MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Miltenyi Biotec
• 10.2. Lonza
• 10.3. Fresenius Kabi
• 10.4. Danaher Corporation
• 10.5. BioSpherix, LLC
• 10.6. Terumo Corporation
• 10.7. Sartorius AG
• 10.8. ThermoGenesis
• 10.9. Cellares Inc.
• 10.10. Thermo Fisher Scientific, Inc.
• 10.11. Merck KgaA

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations